www.fdanews.com/articles/108186-gpc-biotech-kicks-off-phase-ii-trial-for-prostate-cancer-drug
GPC Biotech Kicks Off Phase II Trial for Prostate Cancer Drug
July 1, 2008
GPC Biotech is beginning a clinical trial testing satraplatin combined with the steroid prednisone in patients with metastatic hormone-refractory prostate cancer who have been treated with docetaxel, a chemotherapy drug.
Satraplatin is in the platinum family of compounds and works by targeting DNA tumor cells. It can be taken orally by patients at home while other platinum drugs require intravenous administration, according to GPC.
The Phase II study is being sponsored by the U.S. National Cancer Institute.